Navigation Links
Orexigen® Therapeutics Reports Third Quarter Financial Results
Date:11/8/2011

SAN DIEGO, Nov. 8, 2011 /PRNewswire/ -- Orexigen® Therapeutics, Inc. (Nasdaq: OREX), a biopharmaceutical company focused on the treatment of obesity, today announced financial results for the third quarter of 2011. For the three months ended September 30, 2011, Orexigen reported a net loss of $4.6 million, or $0.10 per share, as compared to a net loss of $14.6 million, or $0.31 per share, for the third quarter of 2010. As of September 30, 2011, Orexigen had $33.9 million in cash and cash equivalents and an additional $29.9 million in marketable securities, for a total of approximately $63.8 million.

"Based on feedback provided in written correspondence from the FDA's Office of New Drugs during the quarter, we were pleased to have identified a very clear and feasible path forward for Contrave®," stated Mike Narachi, Orexigen President and CEO. "We are now working diligently with our partner Takeda to finalize the details of the protocol with the FDA in order to begin enrollment of the cardiovascular outcomes trial (CVOT) in the first half of 2012."

Total operating expenses for the third quarter of 2011 were $5.4 million compared to $14.8 million for third quarter of 2010. This decrease in operating expenses primarily reflects a decrease in research and development expenses of $6.6 million principally related to the decrease in license fees, expenses related to our Contrave development program and salaries and personnel related costs. This overall decrease in operating expenses also reflects a decrease in general and administrative costs of $2.7 million principally related to decreases in salaries and personnel related costs, stock-based compensation expense and medical affairs expense.

Last month, the Company also presented new data in several posters at the annual meeting of The Obesity Society in Orlando, FL.  Data presentations included:

'/>"/>
SOURCE Orexigen Therapeutics, Inc.
Copyright©2010 PR Newswire.
All rights reserved

Page: 1 2 3 4 5

Related biology technology :

1. Orexigen® Therapeutics Announces Upcoming Data Presentations at the 28th Annual Scientific Meeting of The Obesity Society
2. Orexigen® Therapeutics Schedules November 3, 2010 Webcast Discussion of Financial Results for the Third Quarter Ended September 30, 2010
3. Orexigen® Therapeutics to Present at JP Morgan Healthcare Conference
4. Orexigen® Therapeutics Announces Corporate Realignment
5. Orexigen® Therapeutics Announces Upcoming Data Presentation at the American College of Cardiology Annual Scientific Meeting
6. Orexigen® Therapeutics Presents Additional Contrave® Data from Phase 3 COR-II Trial on 24-Hour Ambulatory Blood Pressure Monitoring
7. Orexigen® Therapeutics Announces Multiple Contrave® Data Presentations at the 29th Annual Scientific Meeting of The Obesity Society
8. Halozyme Therapeutics Reports 2008 Second Quarter Financial Results
9. Repair Stem Cell Institute Announces Industrys First Standards of Excellence for Global Stem Cell Treatment Centers to Protect Patients from Less-than-Competent Therapeutics
10. Amsterdam Molecular Therapeutics Reports Half Year Results 2008
11. BN ImmunoTherapeutics Announces Partnership With National Cancer Institute
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:11/24/2014)... -- Senior Vice President, General Manager for ... business acumen Elsevier , a world-leading ... services, congratulates Diane Bartoli , Senior Vice President ... Clinical Solutions, for being recognized in the 13 th ... of Profiles in Diversity Journal ® . ...
(Date:11/22/2014)... MA (PRWEB) November 21, 2014 ... key investors will gather on December 3rd at ... Biotech Conferences series. GeneticRx will take place at ... Medical School and will discuss the present and ... therapy, exon skipping, and gene editing—as well as ...
(Date:11/22/2014)... November 22, 2014 The “Chiral ... Preparative), by Material (Metal, Glass, Plastic), by Application ... SFC] - Forecast to 2018” analyses and studies ... in North America, Europe, Asia, and Rest of ... and 15 figures spread through 135 pages and ...
(Date:11/21/2014)... , Todd Martensen ... Mariano Rodríguez es elegid vicepresidente senior de desarrollo empresarial ... en marcha para comenzar de forma rápida la comercialización de ... aprobación en Europa   , KLOX ... los siguientes nombramientos: Todd Martensen ha ...
Breaking Biology Technology:Elsevier Clinical Solutions' Diane Bartoli Featured In Profiles in Diversity Journal's 13th Annual Women Worth Watching Issue 2Elsevier Clinical Solutions' Diane Bartoli Featured In Profiles in Diversity Journal's 13th Annual Women Worth Watching Issue 3Pioneering Academics and Key Industry Leaders to Discuss Rare Diseases and the Emergence of New Genetic Medicines at Genetic Rx on December 3rd 2Chiral Chromatography Columns Market worth $87.8 Million by 2018 - New Research Report by MarketsandMarkets 2Chiral Chromatography Columns Market worth $87.8 Million by 2018 - New Research Report by MarketsandMarkets 3Chiral Chromatography Columns Market worth $87.8 Million by 2018 - New Research Report by MarketsandMarkets 4Chiral Chromatography Columns Market worth $87.8 Million by 2018 - New Research Report by MarketsandMarkets 5KLOX Technologies anuncia sus nombramientos ejecutivos 2KLOX Technologies anuncia sus nombramientos ejecutivos 3KLOX Technologies anuncia sus nombramientos ejecutivos 4KLOX Technologies anuncia sus nombramientos ejecutivos 5
... Pharmaceuticals,(Nasdaq: VIAP ), a biotechnology company focused on ... announced today that,James G. Stewart, senior vice president and ... Rodman & Renshaw 5th Annual Global,Healthcare Conference on Monday, ... Beach Plaza Hotel in Monte Carlo, Monaco., ...
... Health, a,leading allograft bio-implant company announces that Lloyd ... award at the 11th,Annual Hampton Roads Technology Council,s ... in Innovation award, sponsored by Willcox and Savage,P.C., ... from within,the Hampton Roads region. Hampton Roads Technology ...
... BCRX ) today announced financial results for,the quarter ended March ... quarter of 2008, compared to $9.2M in the first quarter ... 2008 was $13.1M, or,$0.34 per share, compared to a net ... $0.30 per share., Research and development (R&D) expenses were ...
Cached Biology Technology:LifeNet Health Chief Scientific Officer Wins Award 2BioCryst Reports First Quarter 2008 Financial Results and Clinical Update 2BioCryst Reports First Quarter 2008 Financial Results and Clinical Update 3BioCryst Reports First Quarter 2008 Financial Results and Clinical Update 4BioCryst Reports First Quarter 2008 Financial Results and Clinical Update 5BioCryst Reports First Quarter 2008 Financial Results and Clinical Update 6BioCryst Reports First Quarter 2008 Financial Results and Clinical Update 7BioCryst Reports First Quarter 2008 Financial Results and Clinical Update 8
(Date:11/18/2014)... 2014   EyeLock Inc. , a market ... MorphoTrust USA (Safran), a leading U.S. provider ... strategic partnership to offer comprehensive biometric identity solutions ... airport screening and financial services markets. ... consumers through a nationwide network of 1,100 IdentoGO® ...
(Date:11/7/2014)... Dr. Debra Auguste, associate professor, biomedical engineering, in ... College of New York, have identified a molecule ... of the most aggressive forms of breast cancer. ... high mortality rate owing to aggressive proliferation and ... However, Professor Auguste,s team, discovered the overexpression of ...
(Date:11/6/2014)... PITTSBURGH--Speed is an asset for a predator. Except when that ... The tiger beetle, relative to its size, is the fastest ... 120 body lengths per second (at about five miles per ... To take the sprinting gold from the tiger beetle, a ... BUT! The tiger beetle has a problem. At peak speeds, ...
Breaking Biology News(10 mins):EyeLock, MorphoTrust Form Strategic Partnership to Pursue Commercial Enterprise Deployments 2EyeLock, MorphoTrust Form Strategic Partnership to Pursue Commercial Enterprise Deployments 3The tiger beetle: Too fast to see 2
... been described as "molecular switches" and play a role ... and multiple other common cellular functions. Understanding ... cellular mechanisms related to cancer, which is fundamentally a ... rapidly, multiply and migrate into inappropriate places in the ...
... pain (or lumbago) is a common ailment often triggered by something ... to remedy the situation? An exercise machine designed specifically for back ... in the Journal of the American College of Sports Medicine ... help the development and endurance of back muscles, you must focus ...
... his groundbreaking research focusing on population biology and ecology ... researcher Dr. David Secor has been awarded the University ... for Excellence. As a fisheries biologist, a large ... that often have management conflicts: striped bass, bluefin tuna, ...
Cached Biology News:Research pinpoints action of protein linked to key molecular switch 2Exercise therapy for low back pain 2UMCES fisheries biologist Dr. David Secor receives USM Regent's Faculty Award for research 2
... isoprostanes produced from arachidonic acid during lipid peroxidation. ... rat. 8-iso PGE2 inhibits U-46619 or I-BOP-induced platelet ... µM, respectively. When infused into the renal artery ... mg/kg/min, 8-iso PGE2 decreases the GFR and renal ...
... centrifuge offers both high-speed and high-volume ... of rotor options, making it ideal for ... Maximum Versatility , High-speed (up to ... or high-volume (4 x 250mL) swinging bucket ...
...
... submarine gel systems used gasketed gel trays. Turn the ... tank. Turn it back and run the gel - ... Turn & Cast tray is UV transparent. Each tray ... the tray and one in the center. This allows ...
Biology Products: